JP2024546875A5 - - Google Patents

Info

Publication number
JP2024546875A5
JP2024546875A5 JP2024535534A JP2024535534A JP2024546875A5 JP 2024546875 A5 JP2024546875 A5 JP 2024546875A5 JP 2024535534 A JP2024535534 A JP 2024535534A JP 2024535534 A JP2024535534 A JP 2024535534A JP 2024546875 A5 JP2024546875 A5 JP 2024546875A5
Authority
JP
Japan
Prior art keywords
pmhc
binding
domain
antigen
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024535534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546875A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/085689 external-priority patent/WO2023110918A1/en
Publication of JP2024546875A publication Critical patent/JP2024546875A/ja
Publication of JP2024546875A5 publication Critical patent/JP2024546875A5/ja
Pending legal-status Critical Current

Links

JP2024535534A 2021-12-14 2022-12-13 二連型mhc標的化t細胞エンゲージャー Pending JP2024546875A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163289380P 2021-12-14 2021-12-14
US63/289,380 2021-12-14
US202263317256P 2022-03-07 2022-03-07
US63/317,256 2022-03-07
US202263328417P 2022-04-07 2022-04-07
US63/328,417 2022-04-07
PCT/EP2022/085689 WO2023110918A1 (en) 2021-12-14 2022-12-13 Dual mhc-targeting t cell engager

Publications (2)

Publication Number Publication Date
JP2024546875A JP2024546875A (ja) 2024-12-26
JP2024546875A5 true JP2024546875A5 (cg-RX-API-DMAC7.html) 2025-12-23

Family

ID=84887466

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024535534A Pending JP2024546875A (ja) 2021-12-14 2022-12-13 二連型mhc標的化t細胞エンゲージャー

Country Status (8)

Country Link
US (1) US20250002586A1 (cg-RX-API-DMAC7.html)
EP (1) EP4448570A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024546875A (cg-RX-API-DMAC7.html)
KR (1) KR20240116828A (cg-RX-API-DMAC7.html)
AU (1) AU2022413444A1 (cg-RX-API-DMAC7.html)
CA (1) CA3240046A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024007473A (cg-RX-API-DMAC7.html)
WO (1) WO2023110918A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025210181A1 (en) * 2024-04-04 2025-10-09 Cdr-Life Ag Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
AU2003264009A1 (en) 2002-08-15 2004-03-03 Epitomics, Inc. Humanized rabbit antibodies
JP3803790B2 (ja) 2003-02-17 2006-08-02 株式会社東北テクノアーチ 新規なダイアボディ型二重特異性抗体
CN100415765C (zh) 2003-08-07 2008-09-03 宜康公司 兔单克隆抗体的人源化方法
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
JP4902674B2 (ja) 2006-03-09 2012-03-21 エフ.ホフマン−ラ ロシュ アーゲー 抗薬物抗体アッセイ法
CA2673470A1 (en) 2006-12-21 2008-07-03 Macrogenics, Inc. Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity
NZ579594A (en) 2007-03-12 2012-03-30 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
NZ601583A (en) 2007-05-21 2013-08-30 Bristol Myers Squibb Co Novel rabbit antibody humanization methods and humanized rabbit antibodies
NZ581468A (en) 2007-06-25 2012-09-28 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies, and modified antibodies with improved functional properties
CN101688200B (zh) 2007-06-25 2012-08-08 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 单链抗体的基于序列的改造和优化
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
PL2307455T3 (pl) 2008-06-25 2017-09-29 Esbatech, An Alcon Biomedical Research Unit Llc Optymalizacja rozpuszczalności cząsteczek immunowiążących
KR102391731B1 (ko) 2013-01-14 2022-04-27 젠코어 인코포레이티드 신규한 이형이량체 단백질
EP3587448B1 (en) 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
HUE050159T2 (hu) 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
EP4137816B1 (en) 2014-02-11 2025-03-19 Genzyme Corporation Assays for detecting the presence or amount of an anti-drug antibody
JP6696982B2 (ja) 2014-11-26 2020-05-20 ゼンコー・インコーポレイテッドXencor、 Inc. Cd3および腫瘍抗原に結合するヘテロ二量体抗体
WO2018178307A1 (en) 2017-03-31 2018-10-04 Ablynx N.V. Improved immunogenicity assays
US20190016802A1 (en) * 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Dual specificity polypeptide molecule
KR20200142525A (ko) 2018-04-05 2020-12-22 노파르티스 아게 암에 대한 삼중특이성 결합 분자 및 이의 용도
KR20220015382A (ko) * 2019-05-29 2022-02-08 큐 바이오파마, 인크. 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법
CA3148161A1 (en) 2019-09-05 2021-03-11 Adverum Biotechnologies Anti-drug antibody assay
NL2024375B1 (en) * 2019-12-04 2021-08-31 Apo T B V Methods and means for attracting immune effector cells to tumor cells.
AU2020402581A1 (en) * 2019-12-11 2022-06-23 Molecular Partners Ag Designed ankyrin repeat domains with altered surface residues
EP4304726A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Mage-a4 peptide-mhc antigen binding proteins
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same

Similar Documents

Publication Publication Date Title
JP2020186248A5 (cg-RX-API-DMAC7.html)
JP2024177479A (ja) 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトIgM定常領域
JP2024532485A5 (cg-RX-API-DMAC7.html)
US20170210818A1 (en) Constant region antibody fusion proteins and compositions thereof
JP2023504914A5 (cg-RX-API-DMAC7.html)
JP2020506898A5 (cg-RX-API-DMAC7.html)
JP2001521496A (ja) 高い結合活性の多価および多特異的試薬
JP2020500510A5 (cg-RX-API-DMAC7.html)
EP3472205A1 (en) Chimeric antigen receptor
JP2024507540A5 (cg-RX-API-DMAC7.html)
CA3173414A1 (en) Pd-1 agonist multimeric binding molecules
CN119032104A (zh) 抗血清白蛋白纳米抗体及其衍生物
JP2024547218A5 (cg-RX-API-DMAC7.html)
WO2017200796A1 (en) Engineered pd-1 variants
JP2024507693A (ja) 二重特異性抗体
JP2024509910A5 (cg-RX-API-DMAC7.html)
JP2024507693A5 (cg-RX-API-DMAC7.html)
JP2023544211A5 (cg-RX-API-DMAC7.html)
TWI918721B (zh) Egfr結合複合物及其製備和使用方法
JP2024516098A5 (cg-RX-API-DMAC7.html)
JP2016529213A5 (cg-RX-API-DMAC7.html)
CN116888259A (zh) 抗c4d嵌合抗原受体调节性t细胞及其用途
CN113614103A (zh) 不直接向其附着的细胞传导信号的非天然nkg2d受体
JP2021524451A5 (cg-RX-API-DMAC7.html)
CN111201242A (zh) 不对称异二聚fc-scfv融合抗globo h及抗cd3双特异性抗体及其在癌症治疗上的用途